(NASDAQ: CBUS) Cibus's forecast annual revenue growth rate of 214.71% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.62%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.19%.
Cibus's revenue in 2026 is $3,794,000.On average, 6 Wall Street analysts forecast CBUS's revenue for 2026 to be $446,424,305, with the lowest CBUS revenue forecast at $334,166,831, and the highest CBUS revenue forecast at $569,972,666. On average, 5 Wall Street analysts forecast CBUS's revenue for 2027 to be $937,523,610, with the lowest CBUS revenue forecast at $715,071,421, and the highest CBUS revenue forecast at $1,164,047,032.
In 2028, CBUS is forecast to generate $7,710,373,086 in revenue, with the lowest revenue forecast at $3,894,487,516 and the highest revenue forecast at $11,701,810,238.